| Programmable bacteria detect and record an environmental signal in the mammalian gut JW Kotula, SJ Kerns, LA Shaket, L Siraj, JJ Collins, JC Way, PA Silver Proceedings of the National Academy of Sciences 111 (13), 4838-4843, 2014 | 427 | 2014 |
| Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation DT Riglar, TW Giessen, M Baym, SJ Kerns, MJ Niederhuber, RT Bronson, ... Nature biotechnology 35 (7), 653-658, 2017 | 360 | 2017 |
| An engineered E. coli Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans CB Kurtz, YA Millet, MK Puurunen, M Perreault, MR Charbonneau, ... Science translational medicine 11 (475), eaau7975, 2019 | 312 | 2019 |
| Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells JW Kotula, ED Pratico, X Ming, O Nakagawa, RL Juliano, BA Sullenger Nucleic acid therapeutics 22 (3), 187-195, 2012 | 131 | 2012 |
| A distributed cell division counter reveals growth dynamics in the gut microbiota C Myhrvold, JW Kotula, WM Hicks, NJ Conway, PA Silver Nature communications 6 (1), 10039, 2015 | 59 | 2015 |
| Targeted disruption of β-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth JW Kotula, J Sun, M Li, ED Pratico, MP Fereshteh, DP Ahrens, ... PLoS One 9 (4), e93441, 2014 | 49 | 2014 |
| Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier D Falb, VM Isabella, JW Kotula, PF Miller US Patent App. 14/998,376, 2016 | 44 | 2016 |
| Bacteria engineered to treat diseases associated with hyperammonemia D Falb, VM Isabella, JW Kotula, PF Miller, S Machinani US Patent 9,688,967, 2017 | 42 | 2017 |
| Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier D Falb, VM Isabella, JW Kotula, PF Miller, Y Millet, A Fisher US Patent 11,384,359, 2022 | 39 | 2022 |
| Translational Development of Microbiome‐Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates C Kurtz, WS Denney, L Blankstein, SE Guilmain, S Machinani, J Kotula, ... Clinical and translational science 11 (2), 200-207, 2018 | 34 | 2018 |
| Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid D Falb, PF Miller, Y Millet, VM Isabella, JW Kotula, A Tucker US Patent App. 15/379,445, 2017 | 27 | 2017 |
| Repeated measures of blood and breath ammonia in response to control, moderate and high protein dose in healthy men LA Spacek, A Strzepka, S Saha, J Kotula, J Gelb, S Guilmain, T Risby, ... Scientific reports 8 (1), 2554, 2018 | 26 | 2018 |
| Bacteria engineered to treat metabolic diseases D Falb, VM Isabella, JW Kotula, PF Miller, R Sarah, Y Millet, A Fisher US Patent 11,291,693, 2022 | 19 | 2022 |
| Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier D Falb, VM Isabella, JW Kotula, PF Miller US Patent 10,273,489, 2019 | 17 | 2019 |
| Bacteria engineered to reduce hyperphenylalaninemia D Falb, VM Isabella, JW Kotula, PF Miller, Y Millet, R Sarah US Patent 10,610,546, 2020 | 15 | 2020 |
| Bacteria engineered to treat a disease or disorder D Falb, PF Miller, JW Kotula, VM Isabella, S Machinani, AB Fisher, Y Millet US Patent 9,889,164, 2018 | 12 | 2018 |
| Bacteria engineered to treat diseases associated with hyperammonemia D Falb, VM Isabella, JW Kotula, PF Miller, S Machinani US Patent 11,060,073, 2021 | 10 | 2021 |
| Bacteria engineered to treat a disease or disorder D Falb, PF Miller, JW Kotula, VM Isabella, S Machinani, AB Fisher, Y Millet US Patent 10,933,102, 2021 | 10 | 2021 |
| Bacteria engineered to treat disorders involving propionate catabolism D Falb, P Miller, A Tucker, J Kotula, V ISABELLA, Y Millet | 10 | 2017 |
| Bacteria engineered to treat disorders in which oxalate is detrimental V Isabella, D Falb, CL Anderson, P Miller, Y Millet, J Kotula US Patent 11,273,184, 2022 | 7 | 2022 |
